search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
50 BIOTECHNOLOGY


Benevolent AI applies AI tech in the human health and bioscience sectors


answer other questions and extract new information,” says Ferraiuolo. “AI is already extensively used for image analysis in the medical field, I believe in silico models and drug discovery are our present and immediate future,” she adds. Looking ahead throughout 2018,


Hunter says that the focus of the company’s effort will be on the analysis of


clinical data and genomics ‘to see how the technology can be used to impact clinical trials and patient stratification.’ “AI is going to have a massive role in personalised medicine. Te power of AI to harness the available data in order to understand patient endotypes will help us more readily identify the right medicine for the right patient,” she adds.


Improving productivity Elsewhere, Dundee-based company Exscientia is applying its AI-based drug discovery and design capabilities to dramatically improve productivity in the stage from initial chemical design to clinical candidate, the single most expensive part of drug development per launched drug. As Andrew Hopkins, CEO at


The Exscientia management team: Andrew Hopkins, CEO is second left www.scientistlive.com


Exscientia, explains, the company’s goal is, starting from a project definition, to design and advance novel high-quality compounds with excellent therapeutic properties to clinical entry in one and a half years. It does this by applying AI to ‘dramatically reduce the number of compounds required for analysis from typically 2,500 per project using traditional approaches, to just 500 when using AI-driven techniques.’ “Our approach is to fuse the power of AI with the discovery experience of seasoned drug hunters. As a result, the company believes it is the first to automate drug design in a manner surpassing conventional approaches,” he says.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84